US-based Sable Therapeutics has announced plans to sign a licensing agreement with China-based Liuqiang Medical Technology Co. The agreement grants Liuqiang exclusive rights to develop and commercialize Sable’s microneedle patch, which includes SBL-003 and SBL-004, in Greater China. The patch is designed for targeted aesthetic fat reduction through a process known as fat ‘browning’. Additionally, Liuqiang will provide support for the formulation, development, and manufacturing of Sable’s microneedle product on a global scale. The deal includes an undisclosed upfront payment from Liuqiang to Sable Therapeutics.
Sable Therapeutics: Focus on Fat Cell Re-engineering
Established in 2020, Sable Therapeutics is a biotherapeutics company co-founded by Dr. Li Qiang, a prominent fat metabolism researcher at Columbia University Medical Center. The company specializes in the re-engineering of fat cells, focusing on the transformation of ‘white’ fat, which stores excess energy in adults, into ‘brown’ fat. Brown fat is smaller, burns to produce heat for the body, and is more prevalent in infants. Sable’s microneedle technology releases drugs in a targeted manner to facilitate this transformation, allowing for the natural and easy burning of fat. This product is anticipated to serve both aesthetic purposes and as a treatment for obesity.
Liuqiang Medical Technology: A Leader in Soluble Microneedle Production
Liuqiang Medical, a spin-off from Fudan University and Jiaotong University in Shanghai, possesses soluble microneedle production technology that boasts the highest density globally. The company is engaged in research and development for medical beauty applications, anesthesia, and medical products for vascular malformations.-Fineline Info & Tech
